Nilanjan Ghosh, MD, PhD, on New Avenues of CAR T Research in Lymphoma

Video

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed new CAR T-cell therapies being investigated for hematologic malignancies.

“CAR T-cell research is branching into novel antigens, dual targets, allogeneic CAR Ts, and methods to reduce the time needed for an autologous product to be developed. As we see more follow up with this over the next year or few years, we will learn more about them. It's very exciting research.”

As more chimeric antigen receptor (CAR) T-cell therapies come to market, clinicians are beginning to see the long-term impact of these treatments in the clinic. Currently approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies include lisocabtagene maraleucel (Breyanzi), axicabtagene cliolecleucel (Yescarta), brexucabtagene autoleucel (Tecartus) and ciltacabtagene autoleucel (Carvykti).

Nilanjan Ghosh, MD, PhD, chief of the lymphoma division and oncologist at Levine Cancer Institute, is seeing first-hand the impact of these cell therapies in hematologic malignancies. He has experience with these therapies on the clinic side and treats patients with malignancies such as lymphomas.

CGTLive spoke to Ghosh to learn more about new avenues of research with CAR T-cell therapies and what new advances may come up in the next few years. He discussed a few programs of note, including Novartis’ YTB323, Allogene’s ALLO501A, LV20.19, dual-targeted CAR T-cell therapies, and CD30-targeted CAR T-cell therapies.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.